Lipodystrophy syndrome in HIV-infected patients with antirretroviral therapy;Síndrome de lipodistrofia en pacientes con infección por VIH que reciben tratamiento antirretroviral

Medicina Interna de Mexico

Volumn 24, Issue 1, 2008, Pages 8-15

  Castro Sansores, Carlos ^a   Rivero, Adrián Santos ^b   Rendón, Juan Carlos Salazar ^a   Rodríguez, Iván Díaz ^a   Biachi, Renán Góngora ^a   Martínez, Pedro González ^a  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

Antiretroviral therapy; HIV; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; QUESTIONNAIRE; SKINFOLD; TREATMENT DURATION; WAIST HIP RATIO;

EID: 44349140150     PISSN: 01864866     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients whit advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-60.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(7):F51-8.
3. Garg A. Lipodystrophies. Am J Med 2000;108(2):143-52.
4. Mauss S. HIV-associated lipodystrophy syndrome. AIDS 2000;14(supp 13):S197-207.
5. Carr A, Samaras K, Chisholm D, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;351(9119):1881-3.
6. Qaqish RB, Rublein J, Wohl DA. HIV-associated lipodystrophy syndrome. Pharmacotherapy 2000;20(1):13-22.
7. Carr A, Miller J, Law M, Cooper D. A syndrome of lipoatrophy, lactic academia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14(15):F25-32.
8. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354(9184):1112-5.
9. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13(13):1659-67.
10. Galli M, Veglia F, Angarano G, et al. Metabolic and morphological alterations under antiretroviral therapy: preliminary results of Lipodystrophy Italian Multicentre Study (LIMS). Abstracts of the Fifth International Congress on Drug Therapy in HIV Infection. AIDS 2000;14(suppl 4):S54. Abstract P133.
11. Galli M, Cozzi-Lepri A, Ridolfo AL, et al. Incidence of adipose alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Inter Med 2002;162(22):2621-8.
12. Collazos J, Rodríguez-Guardado A, Maradona JA, et al. Factors influencing the development of lipodystrophy in human immunodeficiency virus-infected patients. Scand J Infect Dis 2003;35(5):339-40.
13. Guaraldi G, Murri R, Orlando G, et al. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clin Trials 2003;4(2):99-106.
14. Worm D, Kirk O, Andersen O, et al. Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance. HIV Med 2002;3(4):239-46.
15. a ed. México: Panamericana, 2001;pp:594-669.
16. a ed. México: Mc Graw-Hill-Interamericana, 2002;pp:2-8.
17. Chávez-Ballado G. Distribución de tejido adiposo de acuerdo a Síndrome de lipodistrofia en pacientes con infección por VIH que reciben tratamiento antirretroviral edad, sexo y ocupación en una población Yucateca. TESIS, México: Escuela Nacional de Antropología e Historia, 1995;pp:43-44.
18. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Inmune Defic Syndr 2002;31(1):50-5.
19. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003;4(3):293-301.
20. Avilés-Cobián R, Pavía-Ruz NM, Muños- Hernández MR, Arellano-Montaño SA, Cardiel-Marmolejo L, Sánchez-García AG. Síndrome de lipodistrofia en niños y adolescentes. Abstracts del XLIII Congreso Nacional de la Sociedad Mexicana de Endocrinología y Nutrición. Revista de endocrinología y nutrición 2003.
21. Paton NI, Earnest A, Ng YM, Karim F, Aboulhab J. Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact. Clin Infect Dis 2002;35(10):1244-9.
22. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Inmune Defic Syndr 2003;34(1):58-61.
23. Martínez E, Gatell JM. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome. Curr Opin Infect Dis 1999;12(1):13-9.
24. Engelson ES, Kotler DP, Tan YX, et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 1999;69(6):1162-9.
25. Mallon PW, Miller J, Cooper D, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003;17(7):971-9.
26. Thiébaut R, Daucourt V, Mercié P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitane Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine. Clin Infect Dis 2000;31(6):1482-7.
27. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003;17(10):1503-11.
28. Martínez E, Mocroft A, García-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357(9256):592-8.
29. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002;16(18):2447-54.